Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHMI Trans
PACTR202511896163424Phase 1Not yet recruiting
- Sponsor
- Ifakara Health Institute
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of piperaquine, doxycycline and artemether + lumefantrine in malaria (3 arms), sponsored by Ifakara Health Institute. Primary endpoints: Frequency of solicited and unsolicited adverse events and Magnitude of adverse events. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
piperaquinedoxycyclineartemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202511896163424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511896163424.